Skip to main content
    G

    Geron Corporation (GERN)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $0.94
    -0.03 (-2.60%)

    Market Cap: $622.98M

    Last updated: Nov 17, 2026 at 11:06 AM ET

    Geron Corporation (GERN) Earnings: Report Dates and Results

    Updated Nov 4, 2026. Results come from company earnings reports, and estimates are consensus analyst estimates.

    Geron (GERN) is expected to report earnings on Feb 23, 2027. In the quarter ended Sep 30, 2026, Geron reported EPS of $0.00, above the -$0.01 estimate. It beat the EPS estimate in 6 of the last 8 quarters.

    Earnings

    Performance (10Y)

    Beat Rate
    57%(23/40)
    Avg Surprise
    +13.08%
    Streak
    1 Q

    Upcoming Estimates

    Reports Feb 23, 2027 (est.)Period ending Dec 31, 2026
    EPS Consensus$0.00
    Range-$0.01 - $0.02
    7 analysts
    Revenue Consensus
    $66.75M
    Range$62.71M - $69.97M
    7 analysts
    Reports May 4, 2027 (est.)Period ending Mar 31, 2027
    EPS Consensus$0.01
    Range$0.01 - $0.01
    1 analysts
    EPS Revisions
    0
    1
    30d
    EPS Estimate DriftChange to current
    90d ago$0.00n/a
    60d ago$0.00n/a
    30d ago$0.00n/a
    7d ago$0.00n/a
    Current$0.01
    Revenue Consensus
    $74.49M
    Range$68.46M - $85.60M
    3 analysts

    Next Report

    GERN has an expected report date of Feb 23, 2027.

    GERN Earnings Call

    The latest GERN earnings call transcript on file is labeled 2026Q3.

    Read the 2026Q3 transcript

    Earnings History

    Of the 40 quarters below that had an estimate, GERN beat 23, missed 6 and matched 11. Revenue for the quarter ended Sep 30, 2026 was $60.19M, up 27.4% from $47.23M a year earlier.

    Quarter endedEPSEstimateRangeSurpriseResultYoYAnalystsRevisionsReportedRevenue
    Sep 30, 2026$0.00-$0.01-$0.02 - $0.00+120.00%BeatN/A51 up, 0 downNov 4, 2026$60.19M
    Jun 30, 2026-$0.02-$0.01-$0.01 - -$0.01-100.00%MissN/A20 up, 0 downAug 5, 2026$57.48M
    Mar 31, 2026$0.00-$0.02-$0.02 - -$0.02+75.50%BeatN/A20 up, 0 downMay 6, 2026$51.84M
    Dec 31, 2025-$0.02-$0.03N/A+24.29%BeatN/A20 up, 2 downFeb 25, 2026$48.02M
    Sep 30, 2025-$0.03-$0.03-$0.05 - -$0.030.00%In lineN/A30 up, 1 downNov 5, 2025$47.23M
    Jun 30, 2025-$0.02-$0.03-$0.04 - -$0.01+33.33%BeatN/A50 up, 1 downAug 6, 2025$49.04M
    Mar 31, 2025-$0.03-$0.04-$0.04 - -$0.03+25.00%BeatN/A31 up, 1 downMay 7, 2025$39.60M
    Dec 31, 2024-$0.04-$0.05-$0.06 - -$0.03+23.28%BeatN/A50 up, 1 downFeb 26, 2025$47.54M
    Sep 30, 2024-$0.04-$0.08-$0.10 - -$0.08+50.00%BeatN/A100 up, 0 downNov 7, 2024$28.27M
    Jun 30, 2024-$0.10-$0.10-$0.11 - -$0.100.00%In lineN/A70 up, 0 downAug 8, 2024$882000
    Mar 31, 2024-$0.09-$0.09-$0.10 - -$0.090.00%In lineN/A70 up, 0 downMay 2, 2024$304000
    Dec 31, 2023-$0.09-$0.10-$0.12 - -$0.09+10.00%BeatN/A60 up, 0 downFeb 28, 2024N/A
    Sep 30, 2023-$0.08-$0.10-$0.12 - -$0.09+20.00%BeatN/A60 up, 0 downNov 2, 2023$164000
    Jun 30, 2023-$0.09-$0.08-$0.11 - -$0.07-12.50%MissN/A60 up, 0 downAug 3, 2023$29000
    Mar 31, 2023-$0.07-$0.10-$0.12 - -$0.09+30.00%BeatN/A60 up, 0 downMay 11, 2023N/A
    Dec 31, 2022-$0.10-$0.12-$0.15 - -$0.10+16.67%BeatN/A60 up, 0 downMar 16, 2023N/A
    Sep 30, 2022-$0.10-$0.09-$0.11 - -$0.08-11.11%MissN/A60 up, 0 downNov 3, 2022$297000
    Jun 30, 2022-$0.07-$0.09-$0.10 - -$0.09+22.22%BeatN/A50 up, 0 downAug 11, 2022N/A
    Mar 31, 2022-$0.09-$0.10-$0.11 - -$0.10+10.00%BeatN/A50 up, 0 downMay 9, 2022$123000
    Dec 31, 2021-$0.10-$0.08-$0.09 - -$0.08-25.00%MissN/A50 up, 0 downMar 10, 2022$1.15M
    Sep 30, 2021-$0.08-$0.09-$0.10 - -$0.08+11.11%BeatN/A51 up, 0 downNov 9, 2021N/A
    Jun 30, 2021-$0.09-$0.09-$0.10 - -$0.080.00%In lineN/A5N/AAug 16, 2021$107000
    Mar 31, 2021-$0.09-$0.08-$0.08 - -$0.08-12.50%MissN/A5N/AMay 10, 2021$137000
    Dec 31, 2020-$0.07-$0.06-$0.07 - -$0.06-16.67%MissN/A6N/AMar 11, 2021$50000
    Sep 30, 2020-$0.06-$0.06-$0.06 - -$0.050.00%In lineN/A6N/ANov 5, 2020$108000
    Jun 30, 2020-$0.06-$0.06-$0.07 - -$0.050.00%In lineN/A5N/AAug 6, 2020$43000
    Mar 31, 2020-$0.08-$0.12-$0.17 - -$0.09+33.33%BeatN/A4N/AMay 28, 2020$52000
    Dec 31, 2019-$0.15-$0.19-$0.22 - -$0.19+21.05%BeatN/A5N/AMar 12, 2020$171000
    Sep 30, 2019-$0.08-$0.13-$0.20 - -$0.13+38.46%BeatN/A4N/ANov 6, 2019$131000
    Jun 30, 2019-$0.08-$0.10-$0.11 - -$0.06+20.00%BeatN/A3N/AAug 1, 2019$101000
    Mar 31, 2019-$0.05-$0.05-$0.09 - -$0.050.00%In lineN/A2N/AMay 2, 2019$57000
    Dec 31, 2018-$0.04-$0.04-$0.05 - -$0.040.00%In lineN/A3N/AMar 7, 2019$375000
    Sep 30, 2018-$0.03-$0.05-$0.05 - -$0.05+40.00%BeatN/A2N/ANov 1, 2018$165000
    Jun 30, 2018-$0.04-$0.04-$0.04 - -$0.040.00%In lineN/A2N/AJul 31, 2018$208000
    Mar 31, 2018-$0.04-$0.05N/A+20.00%BeatN/AN/AN/AMay 10, 2018$318000
    Dec 31, 2017-$0.05-$0.05-$0.05 - -$0.040.00%In lineN/A3N/AMar 16, 2018$191000
    Sep 30, 2017-$0.04-$0.05-$0.06 - -$0.04+20.00%BeatN/A3N/ANov 1, 2017$163000
    Jun 30, 2017-$0.04-$0.05-$0.05 - -$0.05+20.00%BeatN/A3N/AAug 9, 2017$174000
    Mar 31, 2017-$0.05-$0.05N/A0.00%In lineN/AN/AN/AMay 9, 2017$537000
    Dec 31, 2016-$0.05-$0.06N/A+16.67%BeatN/AN/AN/AMar 1, 2017$94000
    Last 40 quarters

    Annual EPS

    EPS for the fiscal year ended Dec 31, 2025 was -$0.10, after -$0.27 the year before. It was -$0.18 for the year ended Dec 31, 2016, the oldest of the 10 fiscal years shown.

    Fiscal year endedEPSChange
    Dec 31, 2025-$0.10N/A
    Dec 31, 2024-$0.27N/A
    Dec 31, 2023-$0.33N/A
    Dec 31, 2022-$0.36N/A
    Dec 31, 2021-$0.36N/A
    Dec 31, 2020-$0.27N/A
    Dec 31, 2019-$0.36N/A
    Dec 31, 2018-$0.15N/A
    Dec 31, 2017-$0.18N/A
    Dec 31, 2016-$0.18N/A

    Earnings Calls

    The 8 most recent earnings calls are listed below; the latest, 2026Q3 for the period ended Sep 30, 2026, runs about 3,600 words across 9 speakers.

    CallPeriod endingWordsSpeakersTranscript
    2026Q3Sep 30, 20263,6209
    2026Q2Jun 30, 20263,72410
    2026Q1Mar 31, 20264,05611
    2025Q4Dec 31, 20254,06411
    2025Q3Sep 30, 20255,30211
    2025Q2Jun 30, 20255,54315
    2025Q1Mar 31, 20257,16114
    2024Q4Dec 31, 20246,75815

    2026Q3 Earnings Call

    Opening remarks

    Dawn Schottlandt SVP, Investor Relations and Corporate Affairs Good morning, everyone. Welcome to the Geron Corporation Third Quarter 2026 Earnings Conference Call. Before we begin, please note that during the course of the presentation and question-and-answer session, we will be making forward-looking statements regarding future events, performance, plans, expectations and other projections, including those related to our 2026 financial guidance, our current RYTELO commercialization strategy and related opportunities in the U.S. and the EU, the therapeutic potential of RYTELO, other anticipated clinical and commercial events and related timelines, the sufficiency of our financial resources, and other statements that are not historical fact. These statements, of course, involve risks and uncertainties that could cause actual events, performance and results to differ materially from those contained in these forward-looking statements. Therefore, I refer you to the risks and uncertainties described in today's earnings release under the heading Risk Factors and in Geron's most recent periodic report filed with the SEC, which identify important factors that could cause actual results to differ materially from those contained in these forward-looking statements, as well as future updates to Geron's risk and uncertainty disclosures, including in its upcoming quarterly report on Form 10-Q. Geron undertakes no duty or obligation to update its forward-looking statements. Joining me on today's call are several members of Geron's management team: Harout Semerjian, Chief Executive Officer; Ahmed ElNawawi, our Chief Commercial Officer; Dr. Joseph Eid, Executive Vice President, Research and Development and Chief Medical Officer; and Michelle Robertson, our Chief Financial Officer. With that, I'll turn the call over to Harout to discuss Geron's progress in the third quarter.

    Harout Semerjian CEO Thank you, Dawn, and good morning, everyone. We continue to execute our strategy to build a leading hematology company. We're delivering consistent RYTELO demand growth, reinforcing our confidence in the low-risk MDS U.S. commercial opportunity and RYTELO's growth trajectory over the next several years. We also initiated a gated commercial launch in targeted European markets that gives us the optionality to scale up RYTELO's availability through partnerships. Last week, we announced the discontinuation of the IMpactMF trial evaluating imetelstat in relapsed and refractory myelofibrosis following a recommendation by the independent DMC. We believe this is the right course of action for patients and for Geron. In the third quarter, we continued to see increased prescribing from community practices, leading to quarter-over-quarter demand growth of 10% and net revenue growth of 5%, to $60.1 million. This represents a 27% increase in net revenue year over year. This performance keeps us on track to achieve the mid- to high end of our full-year 2026 net revenue guidance range of $220 million to $240 million and reinforces our confidence that RYTELO has a long growth runway in the U.S.

    Frequently Asked Questions About GERN

    When is Geron's next earnings date?

    Geron's next earnings report is expected for Feb 23, 2027.

    Did GERN beat earnings estimates last quarter?

    Yes. Geron reported EPS of $0.00 for the quarter ended Sep 30, 2026, above the -$0.01 estimate, a 120.00% surprise.

    What EPS do analysts expect from GERN next quarter?

    The consensus EPS estimate for Geron for the quarter ending Dec 31, 2026 is $0.00 from 7 analysts, with estimates from -$0.01 to $0.02.

    How often does GERN beat earnings estimates?

    Geron beat the EPS estimate in 6 of the last 8 quarters, with an average surprise of +25.17%.